Search | Page 6 | Aplastic Anemia and MDS International Foundation


Search results

  1. Allo HSCT Using RIC for Hematological Diseases

    ... have failed or be intolerant to imatinib mesylate. Plasma Cell Leukemia after initial therapy, who achieved at least a partial ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  2. CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

    ... cytomegalovirus (CMV) immunoglobulin M (IgM), or rapid plasma reagin (RPR) (Treponema); donors with prior evidence of hepatitis B ...

    Clinical Trial last updated 04/29/2016 - 12:36pm.

  3. Youmna Kfoury, PhD

    ... cells, we have been banking CD34+ HSPCs and BM plasma when possible from the same patients. We will use plasma to run cytokine arrays to validate any differentially expressed ...

    Grant Recipient last updated 12/15/2016 - 12:56pm.

  4. Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

    ... disappearance of any soft tissue plasmacytomas and < =5% plasma cells in the bone marrow . CR requires two consecutive ...

    Clinical Trial last updated 04/29/2016 - 1:00pm.

  5. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... exercise, that can result in significant increases in plasma CK levels should be avoided while on MEK162 treatment. ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  6. Research Overview - Recent Past Progress and Projections for the Near-Term

    ... levels of which are more than fi vefold elevated in the plasma of MDS patients. It directly activates the MDSCs through a receptor ...

    Interview last updated 02/10/2014 - 9:40am.